NYSE:MYOV - Myovant Sciences Stock Price, Forecast & News

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences Ltd (NYSE:MYOV) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.73) by $0.07. View Myovant Sciences' Earnings History.

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Myovant Sciences.

8 brokers have issued 1 year price targets for Myovant Sciences' stock. Their forecasts range from $20.00 to $34.00. On average, they anticipate Myovant Sciences' share price to reach $26.00 in the next year. This suggests a possible upside of 100.6% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

News stories about MYOV stock have trended extremely negative recently, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Myovant Sciences earned a news impact score of -4.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Myovant Sciences.

Myovant Sciences saw a decrease in short interest during the month of December. As of December 13th, there was short interest totalling 2,860,000 shares, a decrease of 8.9% from the November 28th total of 3,140,000 shares. Based on an average daily volume of 2,470,000 shares, the short-interest ratio is presently 1.2 days. Approximately 9.0% of the shares of the stock are short sold. View Myovant Sciences' Current Options Chain.

Some companies that are related to Myovant Sciences include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), FibroGen (FGEN), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Mirati Therapeutics (MRTX), Allakos (ALLK), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT) and Intercept Pharmaceuticals (ICPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Amarin (AMRN), Intra-Cellular Therapies (ITCI), Sorrento Therapeutics (SRNE), Energy Transfer LP Unit (ET), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Revance Therapeutics (RVNC), Fate Therapeutics (FATE), Viking Therapeutics (VKTX) and Intercept Pharmaceuticals (ICPT).

(MYOV) raised $176 million in an initial public offering (IPO) on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Kim Sablich, Mark Altmeyer, Matthew Lang, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Institutional Ownership Trends for Myovant Sciences.

MYOV stock was bought by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Insider Buying and Selling for Myovant Sciences.

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYOV stock can currently be purchased for approximately $12.96.

Myovant Sciences has a market capitalization of $1.16 billion. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences.

The official website for Myovant Sciences is http://www.myovant.com/.

Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]